Current Immune Aspects of Biologics and Nanodrugs: An Overview Raj Bawa, MS, PhD Immunological Issues with Medicines of Nano Size: The Price of Dimension Paradox János Szebeni, MD, PhD, DSc, and Raj Bawa, MS, PhD Immunotherapy and Vaccines Johanna Poecheim, PhD, and Gerrit Borchard, PhD Site-Specific Antibody Conjugation for ADC and Beyond Qun Zhou, PhD Current Understanding of Interactions between Nanoparticles and the Immune System Marina A. Dobrovolskaia, PhD, Michael Shurin, MD, PhD, and Anna A. Shvedova, PhD Auto-antibodies as Biomarkers for Disease Diagnosis Angelika Lueking, Heike Göhler, and Peter Schulz-Knappe The Acceleated Blood Clearance Phenomenon of PEGylated Nanocarriers Amr S. Abu Lila, PhD, and Tatsuhiro Ishida, PhD Anti-PEG Immunity Against PEGylated Therapeutics Amr S. Abu Lila, PhD, and Tatsuhiro Ishida, PhD Complement Activation: Challenges to Nanomedicine Development Dennis E. Hourcade, PhD, Christine T. N. Pham, MD, and Gregory M. Lanza, MD, PhD Intravenous Immunoglobulin at the Borderline of Nanomedicines and Biologicals: Antithrombogenic Effect via Complement Attenuation Milan Basta, MD, PhD Lessons Learned from the Porcine CARPA Model: Constant and Variable Responses to Different Nanomedicines and Administration Protocols Rudolf Urbanics, MD, PhD, Péter Bedocs, MD, PhD, and János Szebeni, MD, PhD Blood Cell Changes in Complement Activation-Related Pseudoallergy: Intertwining of Cellular and Humoral Interactions Zsófia Patkó, MD, PhD, and János Szebeni, MD, PhD, DSc Rodent Models of Complement Activation-Related Pseudoallergy: Inducers, Symptoms, Inhibitors and Reaction Mechanisms László Dézsi, PhD, László Rosivall, MD, PhD, Péter Hamar, MD, PhD, János Szebeni, MD, PhD, and Gábor Szénási, PhD Immune Reactions in the Delivery of RNA Interference-Based Therapeutics: Mechanisms and Opportunities Kaushik Thanki, PhD, Emily Falkenberg, Monique Gangloff, PhD, and Camilla Foged, PhD Lipid Nanoparticle Induced Immunomodulatory Effects of siRNA Ranjita Shegokar, PhD, and Prabhat Mishra, PhD Nanovaccines against Intracellular Pathogens Using Coxiella burnetii as a Model Organism Erin J. van Schaik, PhD, Anthony E. Gregory, PhD, Gerald F. Audette, PhD, and James E. Samuel, PhD Immunogenicity Assessment for Therapeutic Protein Products Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Products The "Sentinel": A Conceptual Nanomedical Strategy for the Enhancement of the Human Immune System Frank J. Boehm and Angelika Domschke, PhD Immunotherapy for Gliomas and Other Intracranial Malignancies Mario Ganau, MD, PhD, Gianfranco K. I. Ligarotti, MD, Salvatore Chibbaro, MD, PhD, and Andrea Soddu, PhD Engineering Nanoparticles to Overcome Barriers to ImmunotherapyRandall Toy, PhD, and Krishnendu Roy, PhD Metal-Based Nanoparticles and theImmune System: Activation, Inflammation, and Potential Applications Yueh-Hsia Luo, PhD, Louis W. Chang, PhD, and Pinpin Lin, PhD Silica Nanoparticles Effects on Hemostasis Volodymyr Gryshchuk, PhD, Volodymyr Chernyshenko, PhD, Tamara Chernyshenko, Olha Hornytska, PhD, Natalya Galagan, PhD, and Tetyana Platonova, DrSc Valproate-Induced Rodent Model of Autism Spectrum Disorder: Immunogenic Effects and Role of Microglia Prabha S. Awale, PhD, James C. K. Lai, PhD, Srinath Pashikanthi, PhD, and Alok Bhushan, PhD Accelerated Blood Clearance Phenomenon and Complement Activation-Related Pseudoallergy: Two Sides of the Same Coin Amr S. Abu Lila, Janos Szebeni, and Tatsuhiro Ishida Current and Rising Concepts in Immunotherapy: Biopharmaceuticals versus Nanomedicines Matthias Bartneck, PhD Characterization of the Interaction between Nanomedicines and Biological Components: In vitro Evaluation Cristina Fornaguera, MSc, PhD Unwanted Immunogenicity: From Risk Assessment to Risk Management Cheryl Scott Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials Minnie Au, MBBS, Theophilus I. Emeto, PhD, Jacinta Power, MBBS, Venkat N. Vangaveti, PhD, and Hock C. Lai, MBBS SGT-53: A Novel Nanomedicine Capable of Augmenting Cancer Immunotherapy Joe B. Harford, PhD, Sang-Soo Kim, PhD, Kathleen F. Pirollo, PhD, Antonina Rait, PhD, and Esther H. Chang, PhD